TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE)
Brief Summary: The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.


Options:
A: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE
B: Arm Label: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Drug: Placebo Match to SH T00658ID | Arm Label: Ethinyl estradiol, Levonorgestrel (Miranova); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ethinyl estradiol, Levonorgestrel (Miranova), Drug: Placebo Match to SH D593B | Intervention Type: DRUG; Name: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Ethinyl estradiol, Levonorgestrel (Miranova); Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova) | Intervention Type: DRUG; Name: Placebo Match to SH T00658ID; Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo Match to SH D593B; Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova)
C: Arm Label: study group (CCOCP); Type: EXPERIMENTAL; Interventions: Drug: CCOCP | Arm Label: control group (traditional OCP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Traditional OCP | Intervention Type: DRUG; Name: CCOCP; Assigned to Arm(s): study group (CCOCP) | Intervention Type: DRUG; Name: Traditional OCP; Assigned to Arm(s): control group (traditional OCP)
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Qlarista Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol valerate/dienogest | Arm Label: Yasmin Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: ethinylestradiol and drospirenone | Intervention Type: DRUG; Name: estradiol valerate/dienogest; Assigned to Arm(s): Qlarista Group | Intervention Type: DRUG; Name: ethinylestradiol and drospirenone; Assigned to Arm(s): Yasmin Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Brief Summary: To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma.

Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.


Options:
A: Arm Label: VELCADE (bortezomib) monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bortezomib (VELCADE) | Arm Label: DOXIL/CAELYX in combination with VELCADE (bortezomib); Type: EXPERIMENTAL; Interventions: Drug: Bortezomib (VELCADE), Drug: Doxorubicin hydrochloride (DOXIL/CAELYX) | Intervention Type: DRUG; Name: Bortezomib (VELCADE); Assigned to Arm(s): VELCADE (bortezomib) monotherapy | Intervention Type: DRUG; Name: Bortezomib (VELCADE); Assigned to Arm(s): DOXIL/CAELYX in combination with VELCADE (bortezomib) | Intervention Type: DRUG; Name: Doxorubicin hydrochloride (DOXIL/CAELYX); Assigned to Arm(s): DOXIL/CAELYX in combination with VELCADE (bortezomib)
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan/Prednisone/Velcade | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide/Prednisone/Velcade | Intervention Type: DRUG; Name: Melphalan/Prednisone/Velcade; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Thalidomide/Prednisone/Velcade; Assigned to Arm(s): B
C: Arm Label: carfilzomib (A0); Type: EXPERIMENTAL; Interventions: Drug: carfilzomib | Arm Label: carfilzomib (A1); Type: EXPERIMENTAL; Interventions: Drug: carfilzomib | Intervention Type: DRUG; Name: carfilzomib; Assigned to Arm(s): carfilzomib (A0) | Intervention Type: DRUG; Name: carfilzomib; Assigned to Arm(s): carfilzomib (A1)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VELCADE Administered by subcutaneous injection | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: VELCADE Administered by intravenous infusion | Intervention Type: DRUG; Name: VELCADE Administered by subcutaneous injection; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: VELCADE Administered by intravenous infusion; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-Controlled Trial of Montelukast in Maintenance Therapy of Asymptomatic Eosinophilic Esophagitis
Brief Summary: Evaluate clinical effectiveness of oral montelukast compared to placebo on prevention of dysphagia and food impaction in patients with EE.

Also evaluate tolerance and safety of oral montelukast in treatment of EE.


Options:
A: Arm Label: Flovent 1760 mcg; Type: EXPERIMENTAL; Interventions: Drug: Flovent | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Flovent; Assigned to Arm(s): Flovent 1760 mcg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Drug; Type: EXPERIMENTAL; Interventions: Drug: Montelukast/ Singulair | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Montelukast/ Singulair; Assigned to Arm(s): Drug | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Dupilumab 300 mg QW; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg QW | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Mometasone furoat; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate | Arm Label: Placebo spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate; Assigned to Arm(s): Mometasone furoat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo spray

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study
Brief Summary: The investigators' study has 4 primary objectives. Among patients undergoing noncardiac surgery the investigators will determine: (1) the incidence of major perioperative vascular events; (2) the optimal clinical model to predict major perioperative vascular events; (3) the proportion of patients with perioperative myocardial infarctions that may go undetected without perioperative troponin monitoring; and (4) the relationship between postoperative troponin measurements and the 1 year risk of vascular death.


Options:
A: N/A
B: Intervention Type: PROCEDURE; Name: Elective colon cancer surgery; Assigned to Arm(s): N/A
C: Arm Label: Coronary Stent; Type: N/A; Interventions: N/A
D: Arm Label: patients with hip fracture; Type: N/A; Interventions: Other: observation | Intervention Type: OTHER; Name: observation; Assigned to Arm(s): patients with hip fracture

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients
Brief Summary: In critically ill patients, a strategy aimed at an early delivery of full caloric support, with a combination of Enteral Nutrition (EN) and Parenteral Nutrition (PN) (in conditions preventing hyperglycemia and overfeeding), results in shorter ICU and hospital stay and less morbidity as compared to a strategy using only EN.


Options:
A: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Standardized Rehabilitation; Type: OTHER; Interventions: Other: Standardized Rehabilitation | Intervention Type: OTHER; Name: Standardized Rehabilitation; Assigned to Arm(s): Standardized Rehabilitation | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients
Brief Summary: In critically ill patients, a strategy aimed at an early delivery of full caloric support, with a combination of Enteral Nutrition (EN) and Parenteral Nutrition (PN) (in conditions preventing hyperglycemia and overfeeding), results in shorter ICU and hospital stay and less morbidity as compared to a strategy using only EN.


Options:
A: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A
B: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4
D: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients
Brief Summary: In critically ill patients, a strategy aimed at an early delivery of full caloric support, with a combination of Enteral Nutrition (EN) and Parenteral Nutrition (PN) (in conditions preventing hyperglycemia and overfeeding), results in shorter ICU and hospital stay and less morbidity as compared to a strategy using only EN.


Options:
A: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
B: Arm Label: Early parenteral nutrition; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Late parenteral nutrition; Type: EXPERIMENTAL; Interventions: Other: Late parenteral nutrition | Intervention Type: OTHER; Name: Late parenteral nutrition; Assigned to Arm(s): Late parenteral nutrition
C: Arm Label: Tight Glycemic Control 1 (TGC-1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Arm Label: Tight Glycemic Control 2 (TGC-2); Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight Glycemic Control 1 (TGC-1) | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight Glycemic Control 2 (TGC-2)
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: intensive insulin therapy (Actrapid IV to normoglycemia) | Intervention Type: DRUG; Name: intensive insulin therapy (Actrapid IV to normoglycemia); Assigned to Arm(s): B | Intervention Type: DRUG; Name: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia); Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients
Brief Summary: In critically ill patients, a strategy aimed at an early delivery of full caloric support, with a combination of Enteral Nutrition (EN) and Parenteral Nutrition (PN) (in conditions preventing hyperglycemia and overfeeding), results in shorter ICU and hospital stay and less morbidity as compared to a strategy using only EN.


Options:
A: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone sodium succinate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydrocortisone sodium succinate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients
Brief Summary: In critically ill patients, a strategy aimed at an early delivery of full caloric support, with a combination of Enteral Nutrition (EN) and Parenteral Nutrition (PN) (in conditions preventing hyperglycemia and overfeeding), results in shorter ICU and hospital stay and less morbidity as compared to a strategy using only EN.


Options:
A: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
B: Arm Label: Early enteral nutrition; Type: EXPERIMENTAL; Interventions: Drug: early enteral nutrition | Arm Label: Delayed enteral nutrition; Type: ACTIVE_COMPARATOR; Interventions: Drug: Delayed enteral nutrition | Intervention Type: DRUG; Name: early enteral nutrition; Assigned to Arm(s): Early enteral nutrition | Intervention Type: DRUG; Name: Delayed enteral nutrition; Assigned to Arm(s): Delayed enteral nutrition
C: Arm Label: Full enteral feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: Initial enteral feeding | Arm Label: Modified full enteral feeding; Type: EXPERIMENTAL; Interventions: Other: Initial enteral feeding, Drug: metoclopramide or mosapride | Arm Label: Permissive underfeeding; Type: EXPERIMENTAL; Interventions: Other: Initial enteral feeding | Intervention Type: OTHER; Name: Initial enteral feeding; Assigned to Arm(s): Full enteral feeding, Modified full enteral feeding, Permissive underfeeding | Intervention Type: DRUG; Name: metoclopramide or mosapride; Assigned to Arm(s): Modified full enteral feeding
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Full Feeding, Dietary Supplement: Placebo | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids and Antioxidant Supplements; Assigned to Arm(s): 1, 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3, 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients
Brief Summary: In critically ill patients, a strategy aimed at an early delivery of full caloric support, with a combination of Enteral Nutrition (EN) and Parenteral Nutrition (PN) (in conditions preventing hyperglycemia and overfeeding), results in shorter ICU and hospital stay and less morbidity as compared to a strategy using only EN.


Options:
A: Arm Label: SPN group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SPN | Arm Label: Control gr; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: SPN; Assigned to Arm(s): SPN group
B: Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Arm Label: Supplemental PN; Type: EXPERIMENTAL; Interventions: Other: Supplemental PN | Intervention Type: OTHER; Name: Supplemental PN; Assigned to Arm(s): Supplemental PN | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: residual gastric volume; Type: OTHER; Interventions: Procedure: monitoring of residual gastric volume | Arm Label: residual gastric volume not monitored; Type: OTHER; Interventions: Procedure: not monitoring of residual gastric volume | Intervention Type: PROCEDURE; Name: monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume | Intervention Type: PROCEDURE; Name: not monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume not monitored
D: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients
Brief Summary: In critically ill patients, a strategy aimed at an early delivery of full caloric support, with a combination of Enteral Nutrition (EN) and Parenteral Nutrition (PN) (in conditions preventing hyperglycemia and overfeeding), results in shorter ICU and hospital stay and less morbidity as compared to a strategy using only EN.


Options:
A: Arm Label: methylprednisolone; Type: EXPERIMENTAL; Interventions: Drug: intravenous methylprednisolone | Arm Label: normal saline solution; Type: PLACEBO_COMPARATOR; Interventions: Other: intravenous normal saline solution | Intervention Type: DRUG; Name: intravenous methylprednisolone; Assigned to Arm(s): methylprednisolone | Intervention Type: OTHER; Name: intravenous normal saline solution; Assigned to Arm(s): normal saline solution
B: Arm Label: EMS group; Type: EXPERIMENTAL; Interventions: Procedure: EMS | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: EMS; Assigned to Arm(s): EMS group
C: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
D: Intervention Type: DRUG; Name: Mythylprednisolone; Assigned to Arm(s): N/A

Answer: C